Article on Gene Therapy Cites Study Coauthored by Analysis Group Consultants
September 4, 2018
In an article exploring the challenges associated with gene therapies, Forbes cited a recent study conducted by Analysis Group and the National Pharmaceutical Council. The article discussed results from an online survey of managed care organizations, which examined payers' views on alternate payment models for newly developed gene therapies.
Analysis Group Senior Advisor Genia Long, who codirected the study, was quoted extensively in the article. Among the ideas tested in the survey were smoothing payments over time and linking payments to patient outcomes. “There's mutual interest in finding out-of-the-box solutions,” she said. “How we pay for gene therapy will be a measure of how prepared we are to deal with the next generation of innovative treatments.”